An Industry of False Hopes

An Industry of False Hopes

Gilberto Lopes, MD, MBA

@GlopesMD
Feb 24, 2016

Originally published in the Journal of Global Oncology on February 10, 2016; reprinted with permission.

If you peek into a Brazilian household around 10 PM on a weeknight, odds are that at least one television set will be tuned in to Globo TV, a broadcasting behemoth whose programs are watched by 90 million people every day (about the same amount of people who watched the Super Bowl in 2015). Its chief attractions are soap operas. Ranging in themes from historic productions to more modern issues, such as living through an economic downturn, these programs usually run over a period of a few months and have multiple characters and concomitant stories. But even the most creative of soap opera screenwriters could not have imagined a story as convoluted as the one that has been unfolding in Brazil since 2015, which oncologists here have come to know as “phosphogate.”

ANVISA, the health surveillance agency of Brazil, has a strict regulatory process for the registration of new drugs, which is often criticized for being too time-consuming and rigorous. When it comes to cancer drugs, the agency has historically given marketing approval only to those medications that have been assessed in powered randomized clinical trials and, at least until recently, did not usually accept endpoints other than overall survival. As such, medications available worldwide, such as lenalidomide and afatinib, are not considered effective enough and are unavailable to Brazilians. Regulatory issues also plague the conduct of clinical trials because investigators and sponsors are required to submit protocols not only to institutional ethics committees but also to a national one, CONEP (Comissão Nacional de Ética em Pesquisa). This dual process generates delays, with a lead time of up to 12 months before a trial can begin enrollment. These strict regulations are currently being challenged for access to an unproven substance that is reputed to have antineoplastic activity: synthetic phosphoethanolamine.

A key precursor of the biosynthesis of phospholipids in the cellular membrane, and part of the cell signaling system either directly or via second messengers, phosphoethanolamine, in its synthetic version, has been studied by a chemistry professor in one of the campuses of the University of São Paulo, one of the most prestigious tertiary institutions in Brazil. Potential antineoplastic effects have been demonstrated in a few preclinical studies in cell lines and mice models; nonetheless, no appropriate safety studies have been carried out in animals or humans. That has not kept the eager professor from artisanally manufacturing the substance in one of the chemistry laboratories of the university (which is not registered for producing medicines) and distributing it to an increasing number of patients over the years. He claims that nearly 40,000 individuals have been treated. In September 2015, after he retired, the university administration finally decided to stop this nonsensical practice. What appeared to be the end of a problem that did not even merit a footnote in history books actually sparked a spate of lawsuits, forcing the university to maintain the production and distribution of the substance not only to patients who were already using it but also to new ones who were motivated by the attention generated by the news media when production was suspended.

In October 2015, the case reached one of the Brazilian Federal Court judges, who ruled that patients could continue using the substance and that the university laboratory should not stop making phosphoethanolamine, even though it was not accredited to make compounds for human use. Following this decision, additional lawsuits have been brought forward to guarantee the right to treatment for patients without taking into consideration the lack of evidence and the bypassing of the mandated scientific and regulatory process of drug development. In the same month, a hearing in the National Congress demonstrated the commotion of patients who placed all their hope in the supposed drug and clamored for action. After this meeting, the Ministry of Health created and funded (to the tune of US$2.5 million) a task force to conduct preclinical studies and clinical trials to evaluate phosphoethanolamine as a cancer treatment; studies will shortly start at the Cancer Institute of the state of Sao Paulo (ICESP). The upheaval and pressure from groups of patients and family members have been so forceful and misguided that legislators have taken to evaluate the creation of a special track for the regulation of this unproven substance. As of this writing, thousands of lawsuits are making their way through the court systems, and even a fake version of the substance has become available on Internet retail sites.

Although further study may be appropriate, the uncontrolled distribution and use of the substance without proper evidence of its benefits and safety constitute a hazard to public health in Brazil. We expect that society, lawmakers, and the judicial system will come to understand that and redirect this wanton energy into improving our regulatory system for clinical trials and drug approval, speeding up the availability of truly promising drug candidates and proven medications to our patients.

In the 1960s, after an episode which came to be known as the Lobster War (in which French fisherman were driven away by the Brazilian navy for fishing the crustacean within what today would be considered the country´s exclusive economic zone, leading France to send a squadron to the region as well, nearly deflagrating an armed conflict between the two nations), French President Charles de Gaulle reportedly proclaimed that Brazil was not a serious country. It may well be proven that we are not, should the courts and Congress continue to support giving patients phosphoethanolamine. 

Disclaimer: 

The ideas and opinions expressed on the ASCO Connection Blogs do not necessarily reflect those of ASCO. None of the information posted on ASCOconnection.org is intended as medical, legal, or business advice, or advice about reimbursement for health care services. The mention of any product, service, company, therapy or physician practice on ASCOconnection.org does not constitute an endorsement of any kind by ASCO. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in, posted on, or linked to this site, or any errors or omissions.
Back to Top